Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors

Cha, Yu Jin; Kim, Mi-Sook; Jang, Won-Il; Seo, Young Seok; Cho, Chul Koo; Yoo, Hyung Jun; Paik, Eun Kyung

추천

검색

자료유형: 학술저널

저자정보: Cha, Yu Jin (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) Kim, Mi-Sook (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) Jang, Won-Il (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) Seo, Young Seok (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) Cho, Chul Koo (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) Yoo, Hyung Jun (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) Paik, Eun Kyung (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences)

저널정보: 대한방사선종양학회 Radiation oncology journal : ROJ Radiation oncology journal : ROJ 제35권 제2호

발행연도: 2017.1

수록면: 172 - 179 (8page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: To evaluate the outcomes of stereotactic body radiation therapy (SBRT) for patients with liver oligo-recurrence and oligo-progression from various primary tumors. Materials and Methods: Between 2002 and 2013, 72 patients with liver oligo-recurrence (oligo-metastasis with a controlled primary tumor) and oligo-progression (contradictory progression of a few sites of disease despite an overall tumor burden response to therapy) underwent SBRT. Of these, 9 and 8 patients with uncontrollable distant metastases and patients immediate loss to follow-up, respectively, were excluded. The total planning target volume was used to select the SBRT dose (median, 48 Gy; range, 30 to 60 Gy, 3-4 fractions). Toxicity was evaluated using the Common Toxicity Criteria for Adverse Events v4.0. Results: We evaluated 55 patients (77 lesions) treated with SBRT for liver metastases. All patients had controlled primary lesions, and 28 patients had stable lesions at another site (oligo-progression). The most common primary site was the colon (36 patients), followed by the stomach (6 patients) and other sites (13 patients). The 2-year local control and progression-free survival rates were 68% and 22%, respectively. The 2- and 5-year overall survival rates were 56% and 20%, respectively. The most common adverse events were grade 1-2 fatigue, nausea, and vomiting; no grade ${\geq}3$ toxicities were observed. Univariate analysis revealed that oligo-progression associated with poor survival. Conclusion: SBRT for liver oligo-recurrence and oligo-progression appears safe, with similar local control rates. For liver oligo-progression, criteria are needed to select patients in whom improved overall survival can be expected through SBRT.

#Liver metastases #Oligo-recurrence #Oligo-progression #Stereotactic radiation therapy

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!